Search

Your search keyword '"Hay, Kevin"' showing total 268 results
Start Over Author "Hay, Kevin"
268 results on '"Hay, Kevin"'

1. Outcomes with allogeneic stem cell transplant using cryopreserved versus fresh hematopoietic progenitor cell products

Author

Wan, Bo (Angela), Lindo, Lorenzo, Mourad, Yasser Abou, Chung, Shanee, Forrest, Donna, Kuchenbauer, Florian, Nantel, Stephen, Narayanan, Sujaatha, Nevill, Tomas, Power, Maryse, Rodrigo, Judith, Sanford, David, Song, Kevin, Stubbins, Ryan J., Sutherland, Heather, Toze, Cynthia L., White, Jennifer, Roy, Claudie, and Hay, Kevin A.

Published
2024
Full Text
View/download PDF

2. Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22

Author

McComb, Scott, Arbabi-Ghahroudi, Mehdi, Hay, Kevin A., Keller, Brian A., Faulkes, Sharlene, Rutherford, Michael, Nguyen, Tina, Shepherd, Alex, Wu, Cunle, Marcil, Anne, Aubry, Annie, Hussack, Greg, Pinto, Devanand M., Ryan, Shannon, Raphael, Shalini, van Faassen, Henk, Zafer, Ahmed, Zhu, Qin, Maclean, Susanne, Chattopadhyay, Anindita, Gurnani, Komal, Gilbert, Rénald, Gadoury, Christine, Iqbal, Umar, Fatehi, Dorothy, Jezierski, Anna, Huang, Jez, Pon, Robert A., Sigrist, Mhairi, Holt, Robert A., Nelson, Brad H., Atkins, Harold, Kekre, Natasha, Yung, Eric, Webb, John, Nielsen, Julie S., and Weeratna, Risini D.

Published
2024
Full Text
View/download PDF

4. Matched Unrelated Donor Hematopoietic Cell Transplantation: Increased Usage and Improvements in Clinical Outcomes in Canada.

Author

Seftel, Matthew D., Musto, Grace, Allan, David, Bucher, Oliver, Hay, Kevin, Pasic, Ivan, Truong, Tony, and Paulson, Kristjan

Subjects
HEMATOPOIETIC stem cell transplantation, HLA histocompatibility antigens, OVERALL survival, CELLULAR therapy, MUD
Abstract

In allogeneic hematopoietic cell transplantation (HCT), a minority of patients have access to a suitable human leukocyte antigen (HLA)-matched related donor (MRD). To fill this gap, matched unrelated donors (MUDs) are an increasingly selected donor source. Usage and outcomes after MUD HCT for Canada are not described. We investigated temporal trends in MUD compared to MRD HCT from 2000 to 2019 using data reported to the Cell Therapy and Transplant Canada (CTTC) Registry. Of 7571 first allogeneic HCTs between 2000 and 2019, the proportion of MUD HCTs rose from 35.1% to 56.3% in the early (2000–2009) and later (2010–2019) eras, respectively. Comparing the two donor sources, the 5-year overall survival (OS) after MUD HCT for patients with malignant diseases was inferior to MRD HCT in the early era (p < 0.001). However, in the later era, OS was comparable for the two donor sources (p = 0.969). For patients with non-malignant diseases, the 5-year OS after MUD HCT was inferior to MRD in the early era (p < 0.001), but in the later era, the 5-year OS was similar between the two donor sources (p = 0.209). Improvements in OS after MUD HCT were accompanied by corresponding reductions in the 2-year non-relapse mortality after MUD HCT. We conclude that MUDs are the most common donor source in Canada, and key clinical outcomes after MUD have improved over time. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

5. Particle Velocity in Abrasive Waterjets

Author

Lo, Michael, Henning, Axel, Hay, Kevin, Miles, Peter, Cavas-Martínez, Francisco, Series Editor, Chaari, Fakher, Series Editor, Gherardini, Francesco, Series Editor, Haddar, Mohamed, Series Editor, Ivanov, Vitalii, Series Editor, Kwon, Young W., Series Editor, Trojanowska, Justyna, Series Editor, Klichová, Dagmar, editor, Sitek, Libor, editor, Hloch, Sergej, editor, and Valentinčič, Joško, editor

Published
2021
Full Text
View/download PDF

9. Innovations en immunotherapie anticancereuse: therapie par lymphocytes T porteurs de recepteurs antigeniques chimeriques (cellules CAR-T)

Author

Brown, Kevin, Seftel, Matthew D., and Hay, Kevin A.

Subjects
Lymphocytes, Axicabtagene ciloleucel, Immunotherapy, Tisagenlecleucel
Abstract

L'immunotherapie cellulaire est un traitement novateur qui fait appel aux proprietes anticancereuses des cellules immunitaires du corps. L'une des techniques les plus prometteuses est la therapie par lymphocytes T porteurs [...]

Published
2021
Full Text
View/download PDF

12. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Author

Hirayama, Alexandre V., Gauthier, Jordan, Hay, Kevin A., Voutsinas, Jenna M., Wu, Qian, Gooley, Ted, Li, Daniel, Cherian, Sindhu, Chen, Xueyan, Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Steinmetz, Rachel N., Acharya, Utkarsh H., Cassaday, Ryan D., Chapuis, Aude G., Dhawale, Tejaswini M., Hendrie, Paul C., Kiem, Hans-Peter, Lynch, Ryan C., Ramos, Jorge, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., and Turtle, Cameron J.

Published
2019
Full Text
View/download PDF

13. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy

Author

Hay, Kevin A., Gauthier, Jordan, Hirayama, Alexandre V., Voutsinas, Jenna M., Wu, Qian, Li, Daniel, Gooley, Ted A., Cherian, Sindhu, Chen, Xueyan, Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Steinmetz, Rachel N., Schoch, Gary, Chapuis, Aude G., Till, Brian G., Kiem, Hans-Peter, Ramos, Jorge D., Shadman, Mazyar, Cassaday, Ryan D., Acharya, Utkarsh H., Riddell, Stanley R., Maloney, David G., and Turtle, Cameron J.

Published
2019
Full Text
View/download PDF

14. Discovery and Pre-Clinical Development of a Therapeutically Active Nanobody-based Chimeric Antigen Receptor targeting human CD22

Author

McComb, Scott, primary, Arbabi-Gharoudi, Mehdi, additional, Hay, Kevin, additional, Keller, Brian A., additional, Faulkes, Sharlene, additional, Rutherford, Michael, additional, Nguyen, Tina, additional, Shepherd, Alex, additional, Wu, Cunle, additional, Marcil, Anne, additional, Aubry, Annie, additional, Hussack, Greg, additional, Pinto, Devanand M., additional, Ryan, Shannon, additional, Raphael, Shalini, additional, van Faassen, Henk, additional, Zafer, Ahmed, additional, Zhu, Qin, additional, Maclean, Susanne, additional, Chattopadhyay, Anindita, additional, Gurnani, Komal, additional, Gilbert, Rénald, additional, Gadoury, Christine, additional, Iqbal, Umar, additional, Fatehi, Dorothy, additional, Jezierski, Anna, additional, Huang, Jez, additional, Pon, Robert A., additional, Sigrist, Mhairi, additional, Holt, Robert A., additional, Nelson, Brad H., additional, Atkins, Harry, additional, Kekre, Natasha, additional, Yung, Eric, additional, Webb, John, additional, Nielsen, Julie S., additional, and Weeratna, Risini D., additional

Published
2024
Full Text
View/download PDF

18. Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study

Author

Seftel, Matthew D., primary, Pasic, Ivan, additional, Parmar, Gaganvir, additional, Bucher, Oliver, additional, Allan, David S., additional, Bhella, Sita, additional, Hay, Kevin Anthony, additional, Ikuomola, Oluwaseun, additional, Musto, Grace, additional, Prica, Anca, additional, Richardson, Erin, additional, Truong, Tony H., additional, and Paulson, Kristjan, additional

Published
2023
Full Text
View/download PDF

20. Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)

Author

Brown, Kevin, Seftel, Matthew D., and Hay, Kevin A.

Subjects
Care and treatment, Usage, Methods, Health aspects, Genetic engineering -- Methods, Cell therapy -- Methods, Artificial cells -- Usage -- Health aspects, Immunotherapy -- Methods, Leukemia -- Care and treatment, Lymphomas -- Care and treatment, T cells -- Health aspects -- Usage, Cellular therapy -- Methods
Abstract

Cellular immunotherapy is a novel therapy where the body's own immune cells are harnessed for their anticancer effect. One of the most exciting of these approaches is chimeric antigen receptor [...]

Published
2021
Full Text
View/download PDF

22. Figure S6 from Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Author

Gust, Juliane, primary, Hay, Kevin A., primary, Hanafi, Laïla-Aïcha, primary, Li, Daniel, primary, Myerson, David, primary, Gonzalez-Cuyar, Luis F., primary, Yeung, Cecilia, primary, Liles, W. Conrad, primary, Wurfel, Mark, primary, Lopez, Jose A., primary, Chen, Junmei, primary, Chung, Dominic, primary, Harju-Baker, Susanna, primary, Özpolat, Tahsin, primary, Fink, Kathleen R., primary, Riddell, Stanley R., primary, Maloney, David G., primary, and Turtle, Cameron J., primary

Published
2023
Full Text
View/download PDF

23. Data from Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Author

Gust, Juliane, primary, Hay, Kevin A., primary, Hanafi, Laïla-Aïcha, primary, Li, Daniel, primary, Myerson, David, primary, Gonzalez-Cuyar, Luis F., primary, Yeung, Cecilia, primary, Liles, W. Conrad, primary, Wurfel, Mark, primary, Lopez, Jose A., primary, Chen, Junmei, primary, Chung, Dominic, primary, Harju-Baker, Susanna, primary, Özpolat, Tahsin, primary, Fink, Kathleen R., primary, Riddell, Stanley R., primary, Maloney, David G., primary, and Turtle, Cameron J., primary

Published
2023
Full Text
View/download PDF

24. Supplementary text_tables_figurelegends from Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

Author

Gust, Juliane, primary, Hay, Kevin A., primary, Hanafi, Laïla-Aïcha, primary, Li, Daniel, primary, Myerson, David, primary, Gonzalez-Cuyar, Luis F., primary, Yeung, Cecilia, primary, Liles, W. Conrad, primary, Wurfel, Mark, primary, Lopez, Jose A., primary, Chen, Junmei, primary, Chung, Dominic, primary, Harju-Baker, Susanna, primary, Özpolat, Tahsin, primary, Fink, Kathleen R., primary, Riddell, Stanley R., primary, Maloney, David G., primary, and Turtle, Cameron J., primary

Published
2023
Full Text
View/download PDF

25. Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol

Author

Montroy, Joshua, Lalu, Manoj, Kekre, Natasha, Hay, Kevin, McComb, Scott, Weeratna, Risini, Atkins, Harold, Hutton, Brian, Yahya, Ayel, Masurekar, Ashish, Sobh, Mohamad, Ferguson, Dean, and Foster, Madison

Subjects
CAR-T cell therapy, systematic review, oncology, Medicine (miscellaneous), protocol, individual patient data meta-analysis
Abstract

Background Chimeric antigen receptor T cell therapy (CAR-T) represents a promising and exciting new therapy for hematologic malignancies, where prognosis for relapsed/refractory patients remains poor. Encouraging results from clinical trials have often been tempered by heterogeneity in response to treatment among patients, as well as safety concerns including cytokine release syndrome. The identification of specific patient or treatment-specific factors underlying this heterogeneity may provide the key to the long-term sustainability of this complex and expensive therapy. An individual patient data meta-analysis (IPMDA) may provide potential explanations for the high degree of heterogeneity. Therefore, our objective is to perform a systematic review and IPDMA of CAR-T cell therapy in patients with hematologic malignancies to explore potential effect modifiers of CAR-T cell therapy. Methods and analysis We will search MEDLINE, Embase, and the Cochrane Central Register of Controlled Clinical Trials. Studies will be screened in duplicate at the abstract level, then at the full-text level by two independent reviewers. We will include any prospective clinical trial of CAR-T cell therapy in patients with hematologic malignancies. Our primary outcome is complete response, while secondary outcomes of interest include overall response, progression-free survival, overall survival, and safety. IPD will be collected from each included trial and, in the case of missing data, corresponding authors/study sponsors will be contacted. Standard aggregate meta-analyses will be performed, followed by the IPD meta-analysis using a one-stage approach. A modified Institute of Health Economics tool will be used to evaluate the risk of bias of included studies. Ethics and dissemination Identifying characteristics that may act as modifiers of CAR-T cell efficacy is of paramount importance and can help shape future clinical trials in the field. Results from this study will be submitted for publication in a peer-reviewed scientific journal, presented at relevant conferences and shared with relevant stakeholders.

Published
2023

26. Additional file 1 of Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol

Author

Lalu, Manoj M., Kekre, Natasha, Montroy, Joshua, Ghiasi, Maryam, Hay, Kevin, McComb, Scott, Weeratna, Risini, Atkins, Harold, Hutton, Brian, Yahya, Ayel, Masurekar, Ashish, Sobh, Mohamad, and Fergusson, Dean A.

Abstract

Additional file 1. PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist.

Published
2023
Full Text
View/download PDF

29. CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies

Author

Kekre, Natasha, primary, Hay, Kevin A., additional, Webb, John R., additional, Mallick, Ranjeeta, additional, Balasundaram, Miruna, additional, Sigrist, Mhairi K., additional, Clement, Anne-Marie, additional, Nielsen, Julie S., additional, Quizi, Jennifer, additional, Yung, Eric, additional, Brown, Scott D., additional, Dreolini, Lisa, additional, Waller, Daniel D., additional, Smazynski, Julian, additional, Gierc, Nicole S., additional, Loveless, Bianca C., additional, Clark, Kayla, additional, Dyer, Tyler, additional, Hogg, Richard, additional, McCormick, Leah, additional, Gignac, Michael, additional, Bell, Shanti, additional, Chapman, D. Maria, additional, Bond, David, additional, Yong, Siao, additional, Fung, Rachel, additional, Lockyer, Heather M., additional, Hodgson, Victoria, additional, Murphy, Catherine, additional, Subramanian, Ana, additional, Wiebe, Evelyn, additional, Yoganathan, Piriya, additional, Medynski, Liana, additional, Vaillan, Dominique C., additional, Black, Alice, additional, McDiarmid, Sheryl, additional, Kennah, Michael, additional, Hamelin, Linda, additional, Song, Kevin, additional, Narayanan, Sujaatha, additional, Rodrigo, Judith A., additional, Dupont, Stefany, additional, Hawrysh, Terry, additional, Presseau, Justin, additional, Thavorn, Kednapa, additional, Lalu, Manoj M., additional, Fergusson, Dean A., additional, Bell, John C., additional, Atkins, Harold, additional, Nelson, Brad H., additional, and Holt, Robert A., additional

Published
2022
Full Text
View/download PDF

30. Autologous Stem Cell Transplantation for Treatment with Curative Intent in Adult Patients with Acute Lymphoblastic Lymphoma

Author

Bazin, Jessica L., primary, Abou Mourad, Yasser, additional, Forrest, Donna L., additional, Hay, Kevin, additional, Kuchenbauer, Florian, additional, Nantel, Stephen H., additional, Narayanan, Sujaatha, additional, Nevill, Thomas J., additional, Power, Maryse, additional, Rodrigo, Judith A, additional, Roy, Claudie, additional, Sanford, David, additional, Song, Kevin, additional, Stubbins, Ryan J., additional, Sutherland, Heather J., additional, Toze, Cynthia L., additional, White, Jennifer, additional, and Chung, Shanee, additional

Published
2022
Full Text
View/download PDF

32. Clinical Outcomes in Fresh Versus Cryopreserved Hematopoietic Stem Cell Products in British Columbia: A Retrospective Study

Author

Wan, Bo, primary, Lindo, Lorenzo, additional, Cameron, Giovanna, additional, Abou Mourad, Yasser, additional, Chung, Shanee, additional, Forrest, Donna L., additional, Kuchenbauer, Florian, additional, Nantel, Stephen H., additional, Narayanan, Sujaatha, additional, Nevill, Thomas J., additional, Power, Maryse, additional, Rodrigo, Judith A, additional, Sanford, David, additional, Song, Kevin, additional, Stubbins, Ryan J, additional, Sutherland, Heather J., additional, Toze, Cynthia L., additional, White, Jennifer K., additional, Roy, Claudie, additional, and Hay, Kevin A., additional

Published
2022
Full Text
View/download PDF

33. Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Author

Kaedbey, Rayan, primary, Hay, Kevin, additional, Masih-Khan, Esther, additional, Kardjadj, Moustafa, additional, McCurdy, Arleigh, additional, Chu, Michael P., additional, Jimenez-Zepeda, Victor H, additional, Leblanc, Richard, additional, Song, Kevin, additional, Mian, Hira S, additional, Louzada, Martha L, additional, Sebag, Michael, additional, Reiman, Anthony, additional, White, Darrell J, additional, Venner, Christopher P., additional, Stakiw, Julie, additional, Kotb, Rami, additional, Aslam, Muhammad, additional, Bergstrom, Debra, additional, Gul, Engin, additional, and Reece, Donna E., additional

Published
2022
Full Text
View/download PDF

35. A systematic review and metaanalysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.

Author

Fergusson, Nathan J., Adeel, Komal, Kekre, Natasha, Atkins, Harold, and Hay, Kevin A.

Subjects
T cells, LYMPHOBLASTIC leukemia, CD19 antigen, NON-Hodgkin's lymphoma, CHIMERIC antigen receptors
Abstract

Chimeric antigen receptor (CAR) T-cells are an emerging therapy for the treatment of relapsed/refractory B-cell malignancies. While CD19 CAR-T cells have been FDA-approved, CAR T-cells targeting CD22, as well as dual-targeting CD19/CD22 CAR T-cells, are currently being evaluated in clinical trials. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of CD22-targeting CAR T-cell therapies. We searched MEDLINE, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials from inception to March 3rd 2022 for full-length articles and conference abstracts of clinical trials employing CD22- targeting CAR T-cells in acute lymphocytic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL). The primary outcome was best complete response (bCR). A DerSimonian and Laird random-effects model with arcsine transformation was used to pool outcome proportions. From 1068 references screened, 100 were included, representing 30 early phase studies with 637 patients, investigating CD22 or CD19/CD22 CAR T-cells. CD22 CAR T-cells had a bCR of 68% [95% CI, 53-81%] in ALL (n= 116), and 64% [95% CI, 46-81%] in NHL (n= 28) with 74% and 96% of patients having received anti-CD19 CAR T-cells previously in ALL and NHL studies respectively. CD19/CD22 CAR T-cells had a bCR rate of 90% [95% CI, 84-95%] in ALL (n= 297) and 47% [95% CI, 34-61%] in NHL (n= 137). The estimated incidence of total and severe (grade ≥3) CRS were 87% [95% CI, 80-92%] and 6% [95% CI, 3-9%] respectively. ICANS and severe ICANS had an estimated incidence of 16% [95% CI, 9-25%] and 3% [95% CI, 1-5%] respectively. Early phase trials of CD22 and CD19/ CD22 CAR T-cells show high remission rates in ALL and NHL. Severe CRS or ICANS were (1)rare and dual-targeting did not increase toxicity. Variability in CAR construct, dose, and patient factors amongst studies limits comparisons, with long-term outcomes yet to be reported. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

36. Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real‐world outcomes from a population‐based cohort

Author

Stubbins, Ryan J., primary, Stamenkovic, Maria, additional, Roy, Claudie, additional, Rodrigo, Judith, additional, Chung, Shanee, additional, Kuchenbauer, Florian C., additional, Hay, Kevin A., additional, White, Jennifer, additional, Abou Mourad, Yasser, additional, Power, Maryse M., additional, Narayanan, Sujaatha, additional, Forrest, Donna L., additional, Toze, Cynthia L., additional, Sutherland, Heather J., additional, Nantel, Stephen H., additional, Nevill, Thomas J., additional, Karsan, Aly, additional, Song, Kevin W., additional, and Sanford, David S., additional

Published
2022
Full Text
View/download PDF

37. Autologous Stem Cell Transplant Outcome in Classic Hodgkin Lymphoma Patients in the Era of Post-Transplant Brentuximab Vedotin Consolidation

Author

Chung, Shanee, primary, White, Jennifer, additional, Toze, Cynthia L., additional, Sutherland, Heather J., additional, Sanford, David, additional, Rodrigo, Judith Anula, additional, Nevill, Thomas J., additional, Narayanan, Sujaatha, additional, Nantel, Stephen H., additional, Kuchenbauer, Florian, additional, Hay, Kevin A., additional, Forrest, Donna L., additional, Abou Mourad, Yasser, additional, Song, Kevin, additional, and Power, Maryse, additional

Published
2021
Full Text
View/download PDF

41. Real-World Outcomes of Pfts in Screening for Lung Involvement in Chronic Gvhd Post-Allogeneic Stem Cell Transplant: A Retrospective Study of 387 Patients in British Columbia, Canada

Author

Wan, Bo, Mourad, Yasser Abou, Chung, Shanee, Forrest, Donna L., Kuchenbauer, Florian, Nantel, Stephen H., Narayanan, Sujaatha, Nevill, Thomas J., Power, Maryse, Rodrigo, Judith Anula, Sanford, David, Song, Kevin, Stubbins, Ryan J, Sutherland, Heather J., Toze, Cynthia L., White, Jennifer, Roy, Claudie, and Hay, Kevin A

Published
2023
Full Text
View/download PDF

50. Building Canadian capacity for CAR‐T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study

Author

Khalife, Roy, primary, Montroy, Joshua, additional, Grigor, Emma J. M., additional, Fergusson, Dean A., additional, Atkins, Harold, additional, Seftel, Matthew, additional, Presseau, Justin, additional, Thavorn, Kednapa, additional, Holt, Robert A., additional, Hay, Kevin, additional, Lalu, Manoj M., additional, and Kekre, Natasha, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results